Effect of the CCND1 A870G polymorphism on prostate cancer risk: a meta-analysis of 3,820 cases and 3,825 controls

World Journal of Surgical Oncology

Da-Hong Zhang²  Feng Liu²  Xiaolong Qi²  Xiang He²  Lijun Wan¹  Min Zheng² 

[1] Department of Urology, Quzhou People’s Hospital, No. 2 Zhongloudi Street, Quzhou 310014, China;Department of Urology, Zhejiang Provincial People’s Hospital, No.158 Shangtang Road, Hangzhou 310014, Zhejiang, China

关键词: Prostate cancer;    Polymorphism;    CCND1 A870G;   

Others  :  1131045
DOI  :  10.1186/s12957-015-0479-8

 received in 2014-08-11, accepted in 2015-01-22,  发布年份 2015

【 摘 要 】

Background

Cyclin D1 (CCND1) is critical in the transition of the cell cycle from the G1 to S phases, and unbalanced cell cycle regulation is a hallmark of carcinogenesis. Numerous epidemiological studies have evaluated the association between the CCND1 A870G polymorphism and the risk of prostate cancer (PCa). However, these studies have yielded conflicting results.

Methods

In the present study, the possible association above was assessed by a meta-analysis. Eligible articles were identified for the period up to July 2014. Pooled odds ratios (ORs) with 95% confidence intervals (95% CI) were appropriately derived from fixed effects or random effects models.

Results

A total of ten case-control studies, which included 3,820 cases and 3,825 controls, were identified. Overall, the allelic/genotypic association between the G870A polymorphism and prostate cancer was nonsignificant (OR = 1.045, 95% CI = 0.947 to 1.153 for A versus G, P = 0.380; OR = 1.088, 95% CI = 0.896 to 1.321 for AA versus GG, P = 0.393; OR = 1.044, 95% CI = 0.941 to 1.158 for GA versus GG, P = 0.414; OR = 1.053, 95% CI = 0.955 to 1.161 for the dominant model AA + GA versus GG, P = 0.303; OR = 1.072, 95% CI = 0.881 to 1.306 for the recessive model AA versus AA + GA, P = 0.486). Moreover, subgroup analyses according to ethnicity failed to demonstrate a significant association between this polymorphism and prostate cancer. In addition, we also performed a stratified analysis of cases with PCa metastasis, and the results supported the findings of no significant association between CCND1 A870G polymorphism and metastasis risk of PCa.

Conclusions

Our results suggest that the CCND1 A870G polymorphism might not be a potential candidate for predicting prostate cancer risk, including metastasis risk.

【 授权许可】

   
2015 Zheng et al.; licensee BioMed Central.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Peters ME, Ostrander EA: Prostate cancer: simplicity to complexity. Nat Genet 2001, 27:134-5.
• [2]Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al.: Environmental and heritable factors in the causation of cancer–analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
• [3]Zhang Q, Zheng M, Qi XL, Liu F, Mao ZJ, Zhang DH: Effect of NQO1 C609T polymorphism on prostate cancer risk: a meta-analysis. Onco Targets Ther 2014, 7:907-14.
• [4]Kibel AS, Isaacs WB: G(1)/S cell cycle proteins as markers of aggressive prostate carcinoma. Urology 2000, 55:316-22.
• [5]Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, et al.: Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39:41-51.
• [6]Chang BL, Zheng SL, Isaacs SD, Wiley KE, Turner A, Li G, et al.: A polymorphism in the CDKN1B gene is associated with increased risk of hereditary prostate cancer. Cancer Res 2004, 64:1997-9.
• [7]Henner WD, Evans AJ, Hough KM, Harris EL, Lowe BA, Beer TM: Association of codon 72 polymorphism of p53 with lower prostate cancer risk. Prostate 2001, 49:263-6.
• [8]Kibel AS, Suarez BK, Belani J, Oh J, Webster R, Brophy-Ebbers M, et al.: CDKN1A and CDKN1B polymorphisms and risk of advanced prostate carcinoma. Cancer Res 2003, 63:2033-6.
• [9]Suzuki K, Matsui H, Ohtake N, Nakata S, Takei T, Nakazato H, et al.: A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese. J Biomed Sci 2003, 10:430-5.
• [10]Wang L, Habuchi T, Mitsumori K, Li Z, Kamoto T, Kinoshita H, et al.: Increased risk of prostate cancer associated with AA genotype of cyclin D1 gene A870G polymorphism. Int J Cancer 2003, 103:116-20.
• [11]Sherr CJ: Cancer cell cycles. Science 1996, 274:1672-7.
• [12]Abramson VG, Troxel AB, Feldman M, Mies C, Wang Y, Sherman L, et al.: Cyclin D1b in human breast carcinoma and coexpression with cyclin D1a is associated with poor outcome. Anticancer Res 2010, 30:1279-85.
• [13]Kaminagakura E, Werneck da Cunha I, Soares FA, Nishimoto IN, Kowalski LP: CCND1 amplification and protein overexpression in oral squamous cell carcinoma of young patients. Head Neck 2011, 33:1413-9.
• [14]Troncone G, Volante M, Iaccarino A, Zeppa P, Cozzolino I, Malapelle U, et al.: Cyclin D1 and D3 overexpression predicts malignant behavior in thyroid fine-needle aspirates suspicious for Hurthle cell neoplasms. Cancer 2009, 117:522-9.
• [15]Betticher DC, Thatcher N, Altermatt HJ, Hoban P, Ryder WD, Heighway J: Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995, 11:1005-11.
• [16]Sawa H, Ohshima TA, Ukita H, Murakami H, Chiba Y, Kamada H, et al.: Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. Oncogene 1998, 16:1701-12.
• [17]Qin LY, Zhao LG, Chen X, Li P, Yang Z, Mo WN: The CCND1 G870A gene polymorphism and brain tumor risk: a meta-analysis. Asian Pac J Cancer Prev 2014, 15:3607-12.
• [18]Yang J, Liu H, Lu S, Gao M, Du Q, Tang SC: Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects. Oncol Res 2011, 19:519-25.
• [19]He W, Zeng Y, Long J, Zhou Q, Hu Y, Chen M: Genetic polymorphism of G870A and esophageal cancer susceptibility: a meta-analysis. Biomed Rep 2013, 1:303-7.
• [20]Chen Y, Li T, Yu X, Xu J, Li J, Luo D, et al.: The RTK/ERK pathway is associated with prostate cancer risk on the SNP level: a pooled analysis of 41 sets of data from case–control studies. Gene 2014, 534:286-97.
• [21]Comstock CE, Augello MA, Benito RP, Karch J, Tran TH, Utama FE, et al.: Cyclin D1 splice variants: polymorphism, risk, and isoform-specific regulation in prostate cancer. Clin Cancer Res 2009, 15:5338-49.
• [22]Kibel AS, Jin CH, Klim A, Luly J, Roehl AK, Wu WS, et al.: Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate 2008, 68:1179-86.
• [23]Koike H, Suzuki K, Satoh T, Ohtake N, Takei T, Nakata S, et al.: Cyclin D1 gene polymorphism and familial prostate cancer: the AA genotype of A870G polymorphism is associated with prostate cancer risk in men aged 70 years or older and metastatic stage. Anticancer Res 2003, 23:4947-51.
• [24]Mandal RK, Mittal RD: Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol Oncol 2012, 30:555-61.
• [25]Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature 2001, 411:342-8.
• [26]Knudsen KE, Diehl JA, Haiman CA, Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 2006, 25:1620-8.
• [27]Musgrove EA, Caldon CE, Barraclough J, Stone A, Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 2011, 11:558-72.
• [28]Hemminki K, Lorenzo Bermejo J, Forsti A: The balance between heritable and environmental aetiology of human disease. Nat Rev Genet 2006, 7:958-65.
• [29]Yu K, Zhang J, Zhang J, Dou C, Gu S, Xie Y, et al.: Methionine synthase A2756G polymorphism and cancer risk: a meta-analysis. Eur J Hum Genet 2010, 18:370-8.